Overview


According to FutureWise analysis the market for generic pharmaceuticals in 2023 is US$ 392.52 billion, and is expected to reach US$ 754.98 billion by 2031 at a CAGR of 8.52%.

Generic pharmaceuticals account for the majority of the generic pharmaceuticals market. There are several characteristics of generic drugs that are identical to those of branded drugs marketed by private companies, including their dosage form, strength, safety, routes of administration, performance characteristics, and quality. Generic drugs are clinically equivalent to branded drugs in terms of their benefits. Patent rights for branded drugs expire after a generic version of the drug is produced. Many generic drugs are available in the generic pharmaceuticals market, including metformin, metoprolol, acarbose, acebutolol, aztreonam and more Technology such as 3D printing can revolutionize the manufacture of drugs in the generic pharmaceutical market. Improve R D productivity and benefit patients with 3D printed pharmaceuticals. By using 3D printing, drug manufacturers are able to produce drugs in a customized size, shape, and texture, which isn't possible with generic drugs produced in a traditional way.

Generic drugs are cheaper, have the same chemical composition, and are just as strong as branded drugs. When it is a chronic disease, the treatment lasts longer, and the sale of generic drugs increases. Biosimilar, simple generic, and super generic are the primary types of generic pharmaceuticals. The term biosimilar refers to a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, and potency. For numerous therapies including CNS, cardiovascular, dermatologic, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology, the drugs can be administered orally, intravenously, topically, or by inhalation. A hospital pharmacy, a retail pharmacy, and a pharmacy online are some of the distribution channels that are involved.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Generic Pharmaceuticals Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Generic Pharmaceuticals Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Teva Pharmaceuticals
  • Mylan NV
  • Sandoz International GmbH
  • Hospira
  • Sun Pharmaceutical
  • Lupin Limited
  • Endo International Plc
  • Dr Reddy's Laboratories
  • Apotex Holdings
  • Fresenius Kabi Ag
  • Aurobindo Pharma
  • Aspen Pharmacare
  • Sanofi
  • Cipla
  • Hikma Pharmaceuticals
  • Stada Arzneimittel
  • Krka Group
  • Nichi-Iko Pharmaceutical
  • Valeant
  • Zydus Cadila
  • Merck and Co
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Nexus Pharmaceuticals
  • Novo Nordisk
  • Ranbaxy Laboratories Ltd
  • Sawai Pharmaceuticals
  • Novartis AG
  • Pfizer
  • Johnson and Johnson Services

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Therapy

  • CNS
  • Cardiovascular
  • Dermatology
  • Genitourinary/Hormonal,
  • Respiratory
  • Rheumatology
  • Diabetes
  • Oncology

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Type

  • TBiosimilar
  • Simple Generic
  • Super Generic

By Drug Delivery

  • Oral
  • Injectables
  • Dermal/Topical
  • Inhaler

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Generic Pharmaceuticals Market By Therapy, By Distribution Channel, By Type, By Drug Delivery and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Generic Pharmaceuticals Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Generic Pharmaceuticals Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Generic Pharmaceuticals Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Generic Pharmaceuticals Market, By Therapy Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. CNS
        2. Cardiovascular
        3. Dermatology
        4. Genitourinary/Hormonal,
        5. Respiratory
        6. Rheumatology
        7. Diabetes
        8. Oncology

  • 8.   Generic Pharmaceuticals Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 9.   Generic Pharmaceuticals Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. TBiosimilar
        2. Simple Generic
        3. Super Generic

  • 10.   Generic Pharmaceuticals Market, By Drug Delivery Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injectables
        3. Dermal/Topical
        4. Inhaler

  • 11.   North America Generic Pharmaceuticals Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Generic Pharmaceuticals Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country,2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Generic Pharmaceuticals Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Generic Pharmaceuticals Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Teva Pharmaceuticals
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Mylan NV
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sandoz International GmbH
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Hospira
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Sun Pharmaceutical
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Lupin Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Endo International Plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Dr Reddy's Laboratories
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Apotex Holdings
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Fresenius Kabi Ag
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Aurbindo Pharma
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Aspen Pharmacare
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Sanofi
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Cipla
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Hikma Pharmaceuticals
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Stada Arzneimittel
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Krka Group
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Nichi-Iko Pharmaceutical
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Valeant
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Zydus Cadila
            20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Merck & Co
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Mitsubishi Tanabe Pharma
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Momenta Pharmaceuticals
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. Nexus Pharmaceuticals
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Novo Nordisk
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview
        26. Ranbaxy Laboratories Ltd
         26.1. Company Overview
         26.2. Product Portfolio
         26.3. SWOT Analysis
         26.4. Financial Overview
         26.5. Strategic Overview
        27. Sawai Pharmaceuticals
         27.1. Company Overview
         27.2. Product Portfolio
         27.3. SWOT Analysis
         27.4. Financial Overview
         27.5. Strategic Overview
        28. Novartis AG
         28.1. Company Overview
         28.2. Product Portfolio
         28.3. SWOT Analysis
         28.4. Financial Overview
         28.5. Strategic Overview
        29. Pfizer
         29.1. Company Overview
         29.2. Product Portfolio
         29.3. SWOT Analysis
         29.4. Financial Overview
         29.5. Strategic Overview
        30. Johnson & Johnson Services
         30.1. Company Overview
         30.2. Product Portfolio
         30.3. SWOT Analysis
         30.4. Financial Overview
         30.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients